Karl is the Investment Director at Roche Venture Fund. In collaboration with scientific founders and entrepreneurs Karl fosters early stage life science innovation. He focuses on early stage pre-clinical therapeutic companies and synthetic biology. The startup search by entrepreneurs and the biotech industry to translate science into products is an evolving practice. In addition to working with science research organizations, such as UCSF and NIH, on translational programs he also makes angel investments in seed and series A startups. There are already examples where entrepreneurs were able to generate exits in under 18 months.